Zimmer Biomet Holdings (ZBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zimmer Biomet (ZBH) PT Raised to $117 at Truist Securities
October 31, 2024 12:37 PM EDTTruist Securities analyst Richard Newitter raised the price target on Zimmer Biomet (NYSE: ZBH) to $117.00 (from $112.00) while maintaining a Hold rating.
The analyst comments "ZBH's 3Q cc rev beat offset by ~90bps op margin miss; in-line EPS benefited from non-operating items and... More
Oppenheimer Reiterates Outperform Rating on Zimmer Biomet (ZBH)
October 30, 2024 4:28 PM EDTOppenheimer analyst Steven Lichtman reiterated an Outperform rating and $135.00 price target on Zimmer Biomet (NYSE: ZBH).
The analyst comments "3Q24 sales of $1.824B (+4.1% constant-currency) outpaced our/Street's $1.791B/$1.795B on less ERP headwind than expected and better than expected underlying performance, particularly in SET. Knees... More
